Forest Expects Benicar Sales To Increase With 80 Additional Sankyo Reps
Forest expects sales for the antihypertensive Benicar (olmesartan) to increase due to an additional 80 reps from its co-promotion partner Sankyo
More from Archive
More from Pink Sheet
Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.
Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.
Cooperation between health technology assessment bodies across the EU will lead to a better joint clinical assessment process over time, but patients cannot afford a lengthy wait for improvements, speakers at a cell & gene therapy conference said.